Florian B Mayr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3496100/publications.pdf

Version: 2024-02-01

186209 143943 4,945 61 28 57 citations h-index g-index papers 62 62 62 8524 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	13.9	1,419
2	Epidemiology of severe sepsis. Virulence, 2014, 5, 4-11.	1.8	949
3	Infection Rate and Acute Organ Dysfunction Risk as Explanations for Racial Differences in Severe Sepsis. JAMA - Journal of the American Medical Association, 2010, 303, 2495.	3.8	227
4	Effects of Carbon Monoxide Inhalation during Experimental Endotoxemia in Humans. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 354-360.	2.5	189
5	Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood, 2003, 102, 4594-4599.	0.6	165
6	Duffy antigen modifies the chemokine response in human endotoxemia. Critical Care Medicine, 2008, 36, 159-165.	0.4	159
7	Risk of Cardiovascular Events in Survivors of Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1065-1074.	2.5	137
8	Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Medicine, 2019, 45, 1360-1371.	3.9	117
9	Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions. JAMA - Journal of the American Medical Association, 2017, 317, 530.	3.8	106
10	SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting. Annals of Internal Medicine, 2021, 174, 1404-1408.	2.0	100
11	Elevated Hemostasis Markers after Pneumonia Increases One-Year Risk of All-Cause and Cardiovascular Deaths. PLoS ONE, 2011, 6, e22847.	1.1	93
12	Hemostasis in cardiac arrest patients treated with mild hypothermia initiated by cold fluids. Resuscitation, 2009, 80, 762-765.	1.3	83
13	Do hospitals provide lower quality of care to black patients for pneumonia?*. Critical Care Medicine, 2010, 38, 759-765.	0.4	76
14	Identification of LIN28B-bound mRNAs reveals features of target recognition and regulation. RNA Biology, 2013, 10, 1146-1159.	1.5	76
15	Differences in immune response may explain lower survival among older men with pneumonia*. Critical Care Medicine, 2009, 37, 1655-1662.	0.4	69
16	Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clinical Pharmacology and Therapeutics, 2002, 72, 403-410.	2.3	66
17	The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediatedex vivoplatelet function in acute myocardial infarction. Platelets, 2009, 20, 334-340.	1.1	65
18	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	3.9	65

#	Article	IF	CITATIONS
19	Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans. New England Journal of Medicine, 2022, 386, 1375-1377.	13.9	57
20	The Interleukin-6 G(â^174)C Promoter Polymorphism Does Not Determine Plasma Interleukin-6 Concentrations in Experimental Endotoxemia in Humans. Clinical Chemistry, 2004, 50, 195-200.	1.5	54
21	Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clinical Pharmacology and Therapeutics, 2006, 79, 23-34.	2.3	53
22	Endotoxaemia modulates Toll-like receptors on leucocytes in humans. British Journal of Haematology, 2003, 121, 653-656.	1.2	48
23	Children with Chronic Disease Bear the Highest Burden of Pediatric Sepsis. Journal of Pediatrics, 2018, 199, 194-199.e1.	0.9	45
24	Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination. Journal of Infection, 2021, 83, 237-279.	1.7	41
25	1504: IMMUNE CHECKPOINT INHIBITORS IN SEPSIS: A PHASE 1B TRIAL OF ANTI-PD-L1 (BMS-936559). Critical Care Medicine, 2018, 46, 736-736.	0.4	35
26	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. Clinical Infectious Diseases, 2022, 75, 2161-2168.	2.9	35
27	Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thrombosis and Haemostasis, 2003, 90, 898-903.	1.8	34
28	Regulation of Fas (APO-1, CD95) and Fas Ligand Expression in Leukocytes During Systemic Inflammation in Humans. Shock, 2003, 20, 493-496.	1.0	32
29	Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thrombosis Research, 2008, 123, 108-113.	0.8	31
30	COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. Nature Communications, 2022, 13 , .	5.8	29
31	Socioeconomic factors associated with outcome after cardiac arrest in patients under the age of 65. Resuscitation, 2015, 93, 14-19.	1.3	28
32	The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thrombosis and Haemostasis, 2005, 94, 1148-1156.	1.8	27
33	Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. EClinicalMedicine, 2021, 40, 101117.	3.2	25
34	Endotoxin Down-Modulates P-Selectin Glycoprotein Ligand-1 (PSGL-1, CD162) on Neutrophils in Humans. Journal of Clinical Immunology, 2004, 24, 62-65.	2.0	24
35	Pronounced platelet hyperfunction in patients with cardiac arrest achieving restoration of spontaneous circulation*. Critical Care Medicine, 2009, 37, 975-979.	0.4	24
36	Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. Clinical Infectious Diseases, 2022, 75, e849-e856.	2.9	23

#	Article	IF	Citations
37	MMP-8 Genotypes Influence the Inflammatory Response in Human Endotoxemia. Inflammation, 2014, 37, 451-456.	1.7	17
38	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. Clinical Infectious Diseases, 2022, 75, e579-e584.	2.9	17
39	Comparative COVID-19 Vaccine Effectiveness over Time in Veterans. Open Forum Infectious Diseases, 0, ,	0.4	15
40	Prehospital surface cooling is safe and can reduce time to target temperature after cardiac arrest. Resuscitation, 2015, 87, 51-56.	1.3	13
41	EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE (TBC1269) IN EXPERIMENTAL HUMAN ENDOTOXEMIA. Shock, 2008, 29, 475-482.	1.0	11
42	Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis. Clinical Infectious Diseases, 2022, 75, e617-e622.	2.9	10
43	Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift, 2006, 156, 472-480.	0.5	8
44	Cardiac arrest in a 35-year-old pregnant woman with sarcoidosis. Resuscitation, 2012, 83, e151-e152.	1.3	8
45	Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results. Clinical Chemistry and Laboratory Medicine, 2014, 52, 431-436.	1.4	7
46	Upregulation of cytokine mRNA in circulating leukocytes during human endotoxemia. European Cytokine Network, 2017, 28, 19-26.	1.1	6
47	Very long-term survivors of in-hospital and out-of-hospital cardiac arrest show considerable impairment of daily life. Resuscitation, 2022, 173, 192-200.	1.3	5
48	Understanding the sepsis mortality belt: time to buckle down!. Annals of Translational Medicine, 2016, 4, 319-319.	0.7	4
49	Understanding the complex host response in sepsis: is diabetes the key?. Critical Care, 2016, 20, 321.	2.5	3
50	Feasibility of a Home-Based Palliative Care Intervention for Elderly Multimorbid Survivors of Critical Illness. American Journal of Critical Care, 2021, 30, e12-e31.	0.8	3
51	Identifying Survivors of Sepsis at Risk for Adverse Cardiovascular Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 500-501.	2.5	3
52	1953: BILATERAL BLINDNESS AFTER PRONE POSITIONING FOR ACUTE RESPIRATORY DISTRESS SYNDROME. Critical Care Medicine, 2016, 44, 563-563.	0.4	2
53	Size matters! Peripheral blood leukocyte telomere length and survival after critical illness. European Respiratory Journal, 2020, 55, 1902114.	3.1	2
54	1336: UNDERSTANDING THE BURDEN OF UNPLANNED SEPSIS READMISSIONS. Critical Care Medicine, 2016, 44, 409-409.	0.4	1

#	Article	IF	Citations
55	1428: SOCIOECONOMIC STATUS IS NOT ASSOCIATED WITH RISK OF READMISSION IN SEPSIS PATIENTS. Critical Care Medicine, 2018, 46, 698-698.	0.4	1
56	Feasibility of continuous NIRS monitoring during out-of hospital cardiac arrest until 72 hours post-ROSC. Resuscitation, 2019, 142, e10.	1.3	1
57	The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2007, 110, 279-279.	0.6	1
58	"Low-Level―Carbon Monoxide Administration May Carry Risk. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 784-785.	2.5	1
59	Comprehensive pre- and in-hospital near-infrared-spectroscopy can predict outcome parameters in patients after out-of-hospital cardiac arrest – A feasibility study. Resuscitation, 2017, 118, e103.	1.3	0
60	Quality of life in long-term survivors of cardiac arrest. Resuscitation, 2019, 142, e21.	1.3	0
61	Functional Role of the Chemokine Binding Duffy Antigen Receptor Complex (DARC) in Human Inflammation In Vivo Blood, 2006, 108, 20-20.	0.6	0